Methods for treating delirium glucocorticoid receptor-specific antagonists
View Patent ↗This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating delirium. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating delirium in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
1. A method of treating delirium in a patient in need thereof by administration of an amount of a glucocorticoid receptor-specific antagonist effective to ameliorate the symptoms of delirium, with the proviso that the patient be not otherwise in need of treatment with a glucocorticoid receptor-specific antagonist.
2. The method of claim 1 , wherein the glucocorticoid receptor-specific antagonist comprises a steroidal skeleton.
3. The method of claim 2 , wherein the phenyl-containing moiety in the 11-beta position of the steroidal skeleton is a dimethylaminophenyl moiety.
4. The method of claim 3 , wherein the glucocorticoid receptor antagonist comprises mifepristone.
5. The method of claim 4 , wherein the glucocorticoid receptor antagonist is selected from the group consisting of RU009 and RU044.
6. The method of claim 1 , wherein the glucocorticoid receptor antagonist is administered in a daily amount of between about 0.5 to about 20 mg per kilogram of body weight per day.
7. The method of claim 6 , wherein the glucocorticoid receptor antagonist is administered in a daily amount of between about 1 to about 10 mg per kilogram of body weight per day.
8. The method of claim 7 , wherein the glucocorticoid receptor antagonist is administered in a daily amount of between about 1 to about 4 mg per kilogram of body weight per day.
9. The method of claim 1 , wherein the administration is once per day.
10. The method of claim 1 , wherein the mode of administration is oral.
11. The method of claim 1 , wherein the mode of administration is by a transdermal application, by a nebulized suspension, or by an aerosol spray.